JP2017515893A - Ｈｄｌ治療マーカー - Google Patents

Ｈｄｌ治療マーカー Download PDF

Info

Publication number
JP2017515893A
JP2017515893A JP2017508775A JP2017508775A JP2017515893A JP 2017515893 A JP2017515893 A JP 2017515893A JP 2017508775 A JP2017508775 A JP 2017508775A JP 2017508775 A JP2017508775 A JP 2017508775A JP 2017515893 A JP2017515893 A JP 2017515893A
Authority
JP
Japan
Prior art keywords
hdl
hdl therapeutic
subject
dose
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017508775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515893A5 (OSRAM
Inventor
ダスュー，ジャン−ルイ
バーバラス，ロナルド
Original Assignee
セレニス セラピューティクス ホールディング エスアー
セレニス セラピューティクス ホールディング エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレニス セラピューティクス ホールディング エスアー, セレニス セラピューティクス ホールディング エスアー filed Critical セレニス セラピューティクス ホールディング エスアー
Publication of JP2017515893A publication Critical patent/JP2017515893A/ja
Publication of JP2017515893A5 publication Critical patent/JP2017515893A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
JP2017508775A 2014-05-02 2015-04-30 Ｈｄｌ治療マーカー Pending JP2017515893A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988095P 2014-05-02 2014-05-02
US61/988,095 2014-05-02
PCT/IB2015/000854 WO2015173633A2 (en) 2014-05-02 2015-04-30 Hdl therapy markers

Publications (2)

Publication Number Publication Date
JP2017515893A true JP2017515893A (ja) 2017-06-15
JP2017515893A5 JP2017515893A5 (OSRAM) 2018-06-14

Family

ID=54147231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508775A Pending JP2017515893A (ja) 2014-05-02 2015-04-30 Ｈｄｌ治療マーカー

Country Status (14)

Country Link
US (2) US20150316566A1 (OSRAM)
EP (1) EP3137899A2 (OSRAM)
JP (1) JP2017515893A (OSRAM)
KR (1) KR20170003611A (OSRAM)
CN (1) CN106488987A (OSRAM)
AU (1) AU2015260929A1 (OSRAM)
BR (1) BR112016025470A2 (OSRAM)
CA (1) CA2947127A1 (OSRAM)
IL (1) IL248601A0 (OSRAM)
MX (1) MX2016014306A (OSRAM)
PH (1) PH12016502167A1 (OSRAM)
RU (1) RU2016144908A (OSRAM)
SG (1) SG11201609084QA (OSRAM)
WO (1) WO2015173633A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522055A (ja) * 2020-04-16 2023-05-26 アビオニクス ファーマ エスエー 腎臓病を治療するためのｃｅｒ－００１療法
JP2023553609A (ja) * 2020-12-11 2023-12-25 ヘルシンギン ユリオピスト 対象が脂質低下療法に応答する可能性を判定する方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464613A4 (en) * 2016-05-31 2020-01-08 Institut de Cardiologie de Montréal CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
ES2681124B1 (es) * 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
CN108913761B (zh) * 2017-08-10 2022-01-18 施军平 一种用于筛查遗传性肝病的试剂盒
WO2019043201A1 (en) * 2017-09-01 2019-03-07 Sorbonne Universite TRANSCRIPTION FACTOR ZNF471 USED AS THERAPEUTIC AGENT AND BIOMARKER
CN107764890B (zh) * 2017-10-16 2019-12-17 杭州先导医药科技有限责任公司 一种依折麦布对映异构体的区分检测方法
EP3934650A4 (en) * 2019-03-08 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services PROCEDURE FOR EVALUATION OF CARDIOVASCULAR DISEASE OR INFLAMMATION DISEASE USING A NON-INTERCHANGEABLE LIPID PROBE
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
WO2021209808A1 (en) * 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
IL300439A (en) 2020-08-25 2023-04-01 Regeneron Pharma Treatment of sepsis with PCSK9 and LDLR modulators
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN117479834A (zh) 2021-04-15 2024-01-30 阿比奥尼克斯制药公司 基于脂质结合蛋白的复合物在器官保存溶液中的用途
CN113332423A (zh) * 2021-05-26 2021-09-03 华中科技大学同济医学院附属协和医院 一种pcsk9抑制剂在心脏移植术后抗排斥反应中的应用
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
AU2023285382A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
IL317446A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating acute conditions using complexes based on lipid-binding proteins
CN121219001A (zh) 2023-01-13 2025-12-26 阿比奥尼克斯制药公司 脂质结合蛋白分子疗法
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
CN119534676B (zh) * 2024-10-15 2025-08-15 中日友好医院(中日友好临床医学研究所) 代谢标志物在制备监测pb神经毒性产品中的应用及制品

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
JP3754072B2 (ja) 1994-03-22 2006-03-08 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 摂食抑制ペプチド
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU777203B2 (en) 1998-12-30 2004-10-07 Hans Olof Johansson Separation method utilizing liquid-liquid partition
JP2002541129A (ja) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド エーテル化合物、組成物、およびそれらの使用
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001257173B2 (en) 2000-04-21 2005-09-22 Amgen Inc. Apo-ai/aii peptide derivatives
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
AU2002213136B2 (en) 2000-10-11 2007-01-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US6703422B2 (en) 2000-10-11 2004-03-09 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6713507B2 (en) 2000-10-11 2004-03-30 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
AU2002322284A1 (en) 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20040266660A1 (en) 2001-08-20 2004-12-30 Alphonse Hubsch Hdl for the treatment of stroke and other ischemic conditions
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7691965B2 (en) 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
BR0310099A (pt) 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
WO2004010939A2 (en) 2002-07-30 2004-02-05 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004067489A2 (en) 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
DK1641421T3 (en) 2003-07-03 2019-03-11 Hdl Therapeutics Inc Methods and apparatus for producing HDL particle derivatives of reduced lipid content
ATE428411T1 (de) 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
TW200526778A (en) 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
CA2584048C (en) 2004-10-15 2016-08-09 Alan T. Remaley Multi-domain amphipathic helical peptides and methods of their use
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US7749315B2 (en) 2007-04-04 2010-07-06 Xerox Corporation Phase change inks containing colorant compounds
NZ595384A (en) 2007-08-17 2012-03-30 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein A-I
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8343932B2 (en) 2007-10-19 2013-01-01 Pronota N.V. Protease-sensitive site in apolipoprotein A1, therapeutic and diagnostic implications
CA2703962A1 (en) 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
CN102123722A (zh) 2008-06-18 2011-07-13 加利福尼亚大学董事会 改进的胆固醇流出的肽介质
RU2532222C2 (ru) 2009-02-16 2014-10-27 Серенис Терапьютикс Холдинг С.А, Миметики аполипопротеина а-i
HRP20211619T1 (hr) 2009-06-10 2022-02-04 Arbutus Biopharma Corporation Poboljšana formulacija lipida
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
DK2588113T3 (en) 2010-06-30 2017-03-20 Csl Ltd RECONSTITUTED HIGH-DENSITY LIPOPROTEIN FORMULATION AND PROCEDURE FOR PREPARING IT
PT2673296T (pt) 2011-02-07 2019-01-31 Cerenis Therapeutics Holding Sa Complexos de lipoproteínas e sua fabricação e utilização

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LANGMANN T ET AL.: "Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-depen", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 257, no. 1, JPN6019018563, 1999, pages 29 - 33, ISSN: 0004183639 *
NIESOR EJ ET AL.: "STATIN-INDUCED DECREASE IN ABCA1 EXPRESSION VIA MIR33 INDUCTION MAY COUNTERACT CHOLESTEROL EFFLUX BY", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY [ONLINE], vol. 61, no. 10, JPN6019018562, 2013, ISSN: 0004183638 *
TARDIF JC ET AL.: "Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patient", EUROPEAN HEART JOURNAL, vol. 35, no. 46, JPN7019001631, 29 April 2014 (2014-04-29), pages 3277 - 3286, ISSN: 0004183640 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522055A (ja) * 2020-04-16 2023-05-26 アビオニクス ファーマ エスエー 腎臓病を治療するためのｃｅｒ－００１療法
JP2023553609A (ja) * 2020-12-11 2023-12-25 ヘルシンギン ユリオピスト 対象が脂質低下療法に応答する可能性を判定する方法

Also Published As

Publication number Publication date
KR20170003611A (ko) 2017-01-09
IL248601A0 (en) 2016-12-29
MX2016014306A (es) 2017-06-12
AU2015260929A1 (en) 2016-12-15
PH12016502167A1 (en) 2017-01-09
US20180203025A1 (en) 2018-07-19
CA2947127A1 (en) 2015-11-19
WO2015173633A2 (en) 2015-11-19
SG11201609084QA (en) 2016-11-29
US20150316566A1 (en) 2015-11-05
BR112016025470A2 (pt) 2017-08-15
WO2015173633A3 (en) 2016-01-21
RU2016144908A (ru) 2018-06-05
RU2016144908A3 (OSRAM) 2018-12-18
CN106488987A (zh) 2017-03-08
EP3137899A2 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
US20180203025A1 (en) Hdl therapy markers
Degoma et al. Novel HDL-directed pharmacotherapeutic strategies
JP5542166B2 (ja) 荷電リポタンパク質複合体およびその使用
Gautier et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage
Krause et al. Reconstituted HDL for the acute treatment of acute coronary syndrome
Von Eckardstein et al. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins
JP2008534487A5 (OSRAM)
Di Bartolo et al. The apolipoprotein AI mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins
Remaley et al. Novel concepts in HDL pharmacology
JP2006507223A (ja) 脂質代謝異常疾患の治療方法
Castillo-Nunez et al. Triglyceride-rich lipoproteins: their role in atherosclerosis
Kempen et al. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients
Lee et al. FoxO transcription factors are required for hepatic HDL cholesterol clearance
Verdier et al. Targeting high-density lipoproteins: update on a promising therapy
Ndrepepa High-density lipoprotein: a double-edged sword in cardiovascular physiology and pathophysiology
Cao et al. Recombinant high-density lipoproteins and their use in cardiovascular diseases
Tam et al. Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE−/− mice
Barazza et al. The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques
Darabi et al. High-Density Lipoproteins
Giacaglia et al. Unraveling the Pleiotropic Role of High‐Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases
AU2012202223B2 (en) Charged lipoprotein complexes and their uses
Rosenson et al. Contemporary Reviews in Cardiovascular Medicine
Vikstedt The role of phospholipid transfer protein and cholesteryl ester transfer protein in reverse cholesterol transport
WO2018190896A1 (en) Apoe mimetic peptide compositions
Ditiatkovski et al. An Apolipoprotein AI Mimetic Peptide Designed with a Reductionist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107